Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to $83.4 million.

  • Stoke Therapeutics' Cash & Equivalents fell 44.41% to $83.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.4 million, marking a year-over-year decrease of 44.41%. This contributed to the annual value of $128.0 million for FY2024, which is 33.15% down from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Cash & Equivalents is $83.4 million, which was down 17.82% from $101.5 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Cash & Equivalents ranged from a high of $274.8 million in Q1 2025 and a low of $67.8 million during Q2 2022.
  • Its 3-year average for Cash & Equivalents is $170.3 million, with a median of $190.0 million in 2023.
  • As far as peak fluctuations go, Stoke Therapeutics' Cash & Equivalents skyrocketed by 183.47% in 2023, and later crashed by 47.55% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Cash & Equivalents (Quarterly) stood at $113.6 million in 2022, then surged by 68.59% to $191.4 million in 2023, then plummeted by 33.15% to $128.0 million in 2024, then slumped by 44.41% to $83.4 million in 2025.
  • Its Cash & Equivalents was $83.4 million in Q3 2025, compared to $101.5 million in Q2 2025 and $274.8 million in Q1 2025.